MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2459/jcm.0b013e328355a740

Медицинская библиотека · Journal of cardiovascular medicine (Hagerstown, Md.) · 2012

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.

Vaduganathan Muthiah, Gheorghiade Mihai, Pang Peter S, Konstam Marvin A, Zannad Faiez, Swedberg Karl, Grinfeld Liliana, Burnett John C, Krasa Holly B, Zimmer Christopher, Blair John, Ouyang John, Maggioni Aldo P, EVEREST investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Although congestion is the main reason for admission in patients with worsening acute heart failure syndromes, patients presenting with low SBP and renal impairment often do not respond adequately to and may not tolerate traditional diuretic therapy. We sought to determine the short-term hemodynamic effects of tolvaptan in this high-risk population.

METHODS

In a subset analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan trial, 759 patients (18% of total) had elevated blood urea nitrogen (BUN) (> 20  mg/dl) and low SBP (<105  mmHg) at admission. Of these, 386 were randomized to tolvaptan and 373 to placebo.

RESULTS

Demographics and baseline characteristics were similar in both groups. Greater reductions from baseline in body weight were observed for tolvaptan (1.63 ±  2.00 vs. 0.76  ±  1.75  kg, P  <  0.0001 at day 1 and 3.23  ±  3.36 vs. 2.10  ±  3.47  kg, P  <  0.0001 at day 7 or discharge). Greater increases in serum sodium concentration were also observed in the tolvaptan group as early as day 1 (4.41  ±  3.67 vs. 1.32  ±  3.93  mEq/l, P  <  0.0001) and persisted through day 7 or discharge (4.79  ±  4.89 vs. 1.25  ±  5.00  mEq/l, P  <  0.0001). Similarly, improvements in patient-reported dyspnea and investigator-assessed orthopnea were significantly greater in the tolvaptan group as early as day 1 of treatment. These changes were not associated with significant differences in heart rate, SBP, DBP or serum creatinine between patients in the two treatment groups during hospitalization. In-hospital mortality rates (total and cause-specific) were comparable to patients who had presented with SBP more than 105  mmHg and BUN less than 20  mg/dl.

CONCLUSION

In this subgroup analysis of patients with hypotension and renal impairment, tolvaptan improved symptoms, reduced body weight and increased serum sodium as early as inpatient day 1 without adversely affecting blood pressure or renal function.

Для цитирования: Vaduganathan Muthiah, Gheorghiade Mihai, Pang Peter S, Konstam Marvin A, Zannad Faiez, Swedberg Karl, Grinfeld Liliana, Burnett John C, Krasa Holly B, Zimmer Christopher, Blair John, Ouyang John, Maggioni Aldo P, EVEREST investigators. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.. Journal of cardiovascular medicine (Hagerstown, Md.). 2012. DOI: 10.2459/jcm.0b013e328355a740.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.